ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO1128

Sampling Site Matters: A Falsely Elevated Tacrolimus Level After Stopping IV Infusion in a Patient with Central Venous Catheters

Session Information

Category: Trainee Case Report

  • 1902 Transplantation: Clinical

Authors

  • Kadhem, Salam, University of Florida, Gainesville, Florida, United States
  • Al-Ani, Israa, University of Florida, Gainesville, Florida, United States
  • Alquadan, Kawther Farouk, Shands Hospital/University of Florida, Gainesville, Florida, United States
Introduction

Tacrolimus levels abnormalities constitute a major concern to transplant nephrologists. Based on these values; decisions are made to adjust Tacrolimus doses to achieve adequate immunosuppression. The recognition of pitfalls with these laboratory tests becomes crucial to better interpret the accuracy of these results, specifically when dealing with critically ill patients using intravenous Tacrolimus where a large subset of these patients have central venous catheters that are used for infusions and blood sampling. We are reporting a case of falsely elevated Tacrolimus levels after discontinuation of the medication.

Case Description

A 52-year-old male with history of gastroparesis and kidney transplantation in 2011, presented with sever nausea, vomiting and inability to tolerate oral intake including his oral tacrolimus for one day prior to admission. On presentation, his Tacrolimus level was 3.1 ng/mL. Intravenous continuous infusion of Tacrolimus was initiated via a PICC line. Two days later, his symptoms have resolved and subsequently transitioned back to oral Tacrolimus. Next day Tacrolimus trough (drawn from the PICC line after multiple flushes) came back at 38.9 ng/mL, repeated level confirmed to be more than 30 ng/mL. Immediately, his oral tacrolimus was held. Interestingly, he did not exhibit any signs or symptoms of tacrolimus toxicity and his renal function remained stable at baseline. Rechecked daily troughs for the next 3 days were 23, 17 and 19 ng/mL, despite holding tacrolimus. Simultaneous samples were drawn from both PICC line and peripheral vein showed great discrepancy with troughs of 39.0 ng/mL and less than 3.0 ng/mL respectively. Historically, a similar misinterpretation occurred which led to prolonged hospital stay with potential compromise to his immunosuppression.

Discussion

Falsely elevated Tacrolimus levels in samples drawn from central venous catheters have been reported to last several days despite rinsing the catheter. Studies have shown evidence of reversible adsorption of the drug from the inner walls of different catheters.
Raising awareness to this misleading phenomenon helps avoiding dangerous dose reductions of the immunosuppressive drug and unnecessarily prolonged hospital stay. Sampling for Tacrolimus level should always be drawn from peripheral veins.